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Abstract
Background: small B-cell neoplasms can show plasmacytic differentiation and may potentially progress to aggressive
lymphoma (DLBCL). Epstein-Barr virus (EBV) infection may cause the transformation of malignant cells in vitro.
Design and Method: we established VR09 cell line with plasmacytic differentiation, obtained from a case of atypical, non-
CLL B-cell chronic lymphoproliferative disease with plasmacytic features. We used flow cytometry, immunohistochemistry,
polymerase chain reaction, cytogenetic analysis and florescence in situ hybridization in the attempt at thoroughly
characterizing the cell line. We showed VR09 tumorigenic potential in vivo, leading to the development of activated DLBCL
with plasmacytic features.
Results: VR09 cells displayed plasmacytic appearance and grew as spherical tumors when inoculated subcutaneously into
immunodeficient Rag22/2 c-chain2/2 mice. VR09 cell line and tumors displayed the phenotype of activated stage of B cell
maturation, with secretory differentiation (CD19+ CD20+ CD79a+ CD79b+/2 CD138+ cyclin D1- Ki67 80% IgM+ IgD+
MUM1+ MNDA+ CD10- CD22+ CD23+ CD43+ K+, l- Bcl2+ Bcl6-) and they presented episomal EBV genome, chromosome 12
trisomy, lack of c-MYC rearrangement and Myd88 gene mutation, presence of somatic hypermutation in the VH region, and
wild-type p53.
Conclusion: This new EBV-positive cell line may be useful to further characterize in vivo activated DLBCL with plasmacytic
features.
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Introduction
Human lymphoma cell lines and animal models have contrib-
uted significantly to better understand the physiopathology of
hematopoietic tumors. Cell lines are generally characterized by
monoclonal origin, differentiation arrest and sustained prolifera-
tion in vitro, while maintaining most cellular features and specific
genetic alterations of the primitive tumor [1]. However, primitive
malignant cells may change some morphological and phenotypic
features in culture, due to Epstein-Barr virus (EBV) infection. EBV
is a B lymphotropic herpesvirus linked to several B cell
malignancies and capable of transforming human B cell into
permanent lymphoblastoid cell line in vitro [2]. Besides Hodgkin
lymphoma, Burkitt lymphoma, human immunodeficiency virus-
associated lymphomas and post-transplant lymphoproliferative
disorders [3], EBV has been also detected in low-grade
lymphoproliferative diseases such as chronic lymphocytic leukemia
(CLL) where it has been shown to correlate with transformation to
Richter syndrome in some cases [4,5,6].
Many types of small B lymphoid neoplasms can demonstrate
plasmacytic differentiation and specific immunophenotypic or
genetic markers for plasmacytic lymphoma; furthermore, small B-
cell lymphomas with plasmacytic differentiation frequently repre-
sent a diagnostic challenge, and sometimes only a diagnosis of
small B-cell lymphoma with plasmacytic differentiation can be
done [7]. All of these disorders may potentially undergo trans-
formation to large-cell lymphoma [8].
Diffuse large B-cell lymphoma (DLBCL) represents a very
heterogeneous group of aggressive lymphomas. Following the
introduction of gene expression profiling (GEP), it has become
increasingly clear that DLBCL is a biologically and clinically
heterogeneous disorder. Two major categories are now recog-
nized, i.e. germinal center B-cell (GCB) and activated B-cell (ABC)
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types, which are different for the expression of more than 1000
genes. In the attempt at traslating GEP classification into daily
practice, several immunohistochemical algorithms have been
proposed as a surrogate for GEP analysis [9].
Some aggressive DLBCL show the phenotype of terminal B-cell
differentiation and represent a continuum spectrum of lesions that
ranges from conventional activated DLBCL to plasma cell
disorders with specific molecular patterns [10], some of which,
including Myd88, have been recently suggested to correlate with
plasmacytic lymphoma histotype [11,12].
We describe here the established VR09 cell line, an EBV-
positive cell line with plasmacytic differentiation displaying
tumorigenic potential in vivo and leading to the development of
activated DLBCL with plasmacytic features when injected into
Rag22/2 c-chain2/2 mice. Thus, VR09 xenotrasplantation can
be used successfully as preclinical model for human DLBCL with
plasmacytic differentiation to further characterize this disease.
Materials and Methods
Cell Collection and Culture
A 75-year old Caucasian man was admitted to hospital in
September 2008 for fever, neutropenia and lymphocytosis (WBC
20.16109/L, with neutrophils 0.86109/L and lymphocytes
18.26109/L), and moderate anemia and trombocytopenia (Hb
9 g/dl, PLTS 936109/L). No significant superficial lymphoade-
nopathy or splenomegaly were present. Peripheral blood smear
shows the predominance of small-medium sized mature lymphoid
cells with abundant cytoplasm and compact chromatin
(Figure 1A). A bone marrow sample was sent to our laboratory
for first level-immunophenotyping by flow cytometry (FACS-
Canto, Becton Dickinson Biosciences, CA, USA), after written
informed consent, as approved by the Ethics Committee of
Azienda Ospedaliera Universitaria Integrata Verona (N. Prog.
1828, May 12, 2010 - ‘Institution of cell and tissue collection for
biomedical research in Onco-Hematology’). Bone marrow smear
appeared infiltrated (60%) by a cell population of lymphoplasmo-
cytoid elements of small-medium size (Figure 1B). First level-
immunophenotyping showed the presence of a cell population
expressing CD19, CD20, CD22, CD138, surface immunoglobu-
lins (sIg) at high level, and negative for CD5, CD10, ZAP-70, thus
suggesting the diagnosis of non-CLL atypical B-cell chronic
lymphoproliferative disease with plasmacytic features. No other
exams could be performed, as the patient died of sepsis the
following day.
Mononuclear cells were purified from bone marrow sample by
Ficoll-Paque centrifugation (Lymphoprep, Fresenius Kabi Norge
AS for Axis-Shield Poc AS, Oslo, Norway), washed in phosphate-
buffered saline solution (PBS) and resuspended at 16106/mL
concentration in RPMI 1640+ GlutaMAX 1X containing 10%
heat-inactivated fetal bovine serum and 1% penicillin/streptomy-
cin (all from GIBCO, Invitrogen). Cells were cultured in 75 cm2
flask and incubated in humidified 5% CO2 atmosphere at 37uC.
Half of culture medium was replaced every 3–4 days maintaining
the same cell density of 16106 cells/mL. To determine growth
kinetics, cells were seeded at lower density (350,000/mL) and
counted at 0, 24, 48 and 72 hours by flow-cytometry (FACSCanto,
Becton Dickinson, Italy). No mitogens or growth factors were
added during culture. Cells were maintained in culture up to one
Figure 1. Morphology of primary malignant cells and VR09 cell line. Morphological features of patient’s primary cells and VR09 cells in
suspension, as assessed by May-Gru¨nwald-Giemsa staining. (A) Patient’s peripheral blood cells. (B) Patient’s bone marrow cells. (C) VR09 cells: small
and round clumps in suspension. (D) VR09 cells: plasmacytoid appearance, with irregular nucleus, compact chromatin and abundant basophilic
cytoplasm.
doi:10.1371/journal.pone.0052811.g001
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year. Cell morphology was evaluated on cytospins stained with
May-Grunwald Giemsa dye.
Immunophenotypic Analysis
Cell vitality was assessed by acridine-orange/ethidium bromide
staining and epifluorescent microscopy. Aliquots of 36105 cells
were incubated for 15 minutes at room temperature with three-
color combinations of appropriate monoclonal antibodies anti-
human CD3, CD19, CD20, CD22, CD23, CD25, CD38, CD43,
CD45, FMC-7, CD79b 7AAD (Becton Dickinson, Italy), CD5,
CD10, K, l, IgG, IgM, IgD (Dako, Italy), CD103 (Beckman
Coulter, Italy), CD138 (Cytognos, Italy), and isotype controls
(Becton Dickinson, Italy). Samples were analyzed by FacsCANTO
flow cytometer with BD FACSDiva software (Becton Dickinson,
Italy).
Cell Cycle
For determination of the DNA content, 1.56105 cells were
incubated with 1 ml of staining solution including 5 ml of
hypotonic solution, 50 mg of propidium iodide (Bender MedSys-
tems) and 20 mg of RNAse for two hours at 4uC analyzed using
appropriate settings by FacsCanto flow cytometer. Human
peripheral mononuclear cells were used as control for the
comparison of S fraction.
DNA and RNA Extraction, cDNA Synthesis
DNA and RNA were obtained from 107 cells by AllPrep DNA/
RNA/Protein Mini Kit (Quiagen, Hilden, Germany). DNA
quality was verified by spectrophotometry and RNA quality by
the Agilent Bionanalyzer 2100; 1 mg of total RNA was reverse-
transcribed by using SuperScript III First-Strand Synthesis System
(Invitrogen, Carlsbad, California) and cDNA was used as
a template for reverse transcriptase polymerase chain reaction
(RT-PCR) amplification using listed in Table 1.
Analysis of VH Rearrangement, p53, CD79B, Card 11 and
MYD88 Mutation
To verify the identity between cells from the patient and the cell
line, rearranged VH genes were analyzed as previously described
[13] in frozen DNA from both the patient and the cell line TP53,
Table 1. Primers used to amplify and sequence P53, Card 11, CD79B, MYD88 AND RPMS1 genes.
Primers Sequence Tau Amplicon lenght
P53-1-F AAGTCTAGAGCCACCGTCCA 55uC 771 bp
P53-1-R AAGTGTTTCTGTCATCCAAATACTC
P53-2-F AGCCAAGTCTGTGACTTGCA 55uC 851 bp
P53-2-R GGGGAACAAGAAGTGGAGAA
Card11-1-F AGATGCAACGGGAGCCTGGC 55uC 631 pb
Card11-1-R AGGTTAGCAGCTCCACGCGC
Card11-2-F GGCCAAGGACCTGCAACGCT 55uC 703 pb
Card11-2-R CCGCTCCACCTCCTCCAGCT
Card11-3-F GAGGCCCTGGAGGACAGGCA 55uC 690 pb
Card11-3-R TCCGCAGGAGCTAGGGCTGG
Card11-4-F TCCTGCCCTACCATCCGCCC 55uC 671 pb
Card11-4-R CAGCAGCTGGTGGCCCTCAC
Card11-5-F TCCCAGCTCACCCTGCTGGG 55uC 739 pb
Card11-5-R CCGAGATGATGCGGACCCGC
Card11-6-F CCCGTCTCTCGCGAGCAAGC 55uC 928 pb
Card11-6-R CGTCTGCTGGGGCAGCTCTG
CD79B-1-F GCCTCGGACGTTGTCACGGG 55uC 858 pb*
CD79B-1-R TGGGCCAGCTTCAGAGGCCA
MYD88-EX1F CGCAGGAGAAAGAGGAAGC 60uC 491 bp
MYD88-EX1R ATGGGAGACAGGATGCTGAG
MYD88-EX3F TGGGTAAAGAGGTAGGCACTCCCAG 60uC 275 bp
MYD88-EX2R GCCCATCTGCTTCAAACACCCATGC
MYD88-EX3F AAGCCTTCCCATGGAGCTCTGACCAC 60uC 311 bp
MYD88-EX3R GCTAGGAGGAGATGCCCAGTATCTG
MYD88-EX3F ACTAAGTTGCCACAGGACCTGCAGC 60uC 194 bp
MYD88-EX3R ATCCAGAGGCCCCACCTACACATTC
MYD88-EX3F GTTGTTAACCCTGGGGTTGAAG 60uC 297 bp
MYD88-EX3R GCAGAAGTACATGGACAGGCAGACAGATAC
RPMS1F GGATGGGAGAGGGTGATCTT 60uC 151 bp
RPMS1R ACGTGGAGTTTGCAGTCCTC
Isoform 1: 858 pb; Isoform 2: 546 pb; Isoform 3: 861 pb.
doi:10.1371/journal.pone.0052811.t001
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CD79B and CARD11 genes were amplified and sequenced by using
the primers reported in Table 1. MYD88 exons 1 to 5 were
sequenced as previously described [11,12]. VH and CD79B PCR
bands were excised from agarose gels and purified by using spin
columns (PureLink Quick Gel Extraction and PCR Purification
Combo Kit, Invitrogen). PCR products were sequenced by dye
terminator reaction (Big Dye Terminator Cycle Sequencing Kit
v.3.1, Applied Biosystems, Warrington, UK) on AB3130XL
automated sequencer (Applied Biosystems). TP53, CARD11 and
MYD88 PCR products were directly purified with magnetic beads
(Agencourt AMPure XP, Beckman Coulter Genomics, Beverly,
Massachussets, USA) and sequenced as reported above and by
outsourcing to Base Clear BV (Leiden, The Netherlands).
VH genes sequences were compared to published germline
sequences using IgBLAST (http://www.ncbi.nlm.nih.gov/igblast/
). Sequences with 2% or less deviation from any germline IgVH
sequence were considered unmutated. TP53, CD79B, CARD11
and MYD88 amplified sequences were compared to reference
sequences by using Geneious software (Biomatters Ltd., Auckland,
New Zealand).
Table 2. Marker expression by VR09 cell line and tumor masses, as assessed by immunohistochemistry performed on FFPE cell
block.
Antibody Species Clone Source Diluition VR09 cell line Tumor masses
Annexin a1 mouse B01P Abnova 100 neg neg
Bcl-2 mouse 124 Dako 40 pos pos
Bcl-6 mouse LN22 Novocastra 20 neg neg
Cyclin D1 rabbit SP4 Neomarkers 10 neg neg
CD03 rabbit SP7 Labvision 150 neg neg
CD05 mouse 4C7 Novocastra 200 neg neg
CD10 mouse 56C6 Novocastra 50 neg neg
CD19 mouse LE-CD19 Serotec 200 pos pos
CD20 mouse L26 Novocastra 100 pos pos
CD22 mouse FPC1 Novocastra 20 pos pos
CD23 mouse 1B12 Novocastra 100 pos pos
CD25 IL2R mouse 4C9 Novocastra 100 pos/neg pos/neg
CD38 mouse 38C03 Neomarkers 50 neg pos/neg
CD43 (T cell) mouse MT1 Novocastra 30 pos pos
CD79alfa mouse JCB117 Dako 100 pos pos
CD79beta mouse JS01 Novocastra 50 pos/neg pos/neg
CD123 mouse 7G3 Bd 100 neg pos/neg
CD138 (syndecan-1) mouse BB4 Serotec 50 pos/neg pos/neg
DBA44 hairy cell mouse DBA.44 Dako 20 neg neg
FOXP1 mouse JC12 Abcam 500 neg pos/neg
EBV (EBER) mRNA probe* Vision Byosistems pos pos
GCET1 mouse RAM341 Abcam 500 neg neg
HHV-8 mouse 13B10 Novocastra 50 neg neg
IgD rabbit polyclonal Dako 20 pos pos/neg
IgG rabbit polyclonal Dako 10000 neg neg
IgM rabbit polyclonal Dako 5000 pos/neg pos/neg






ZAP-70 mouse 2F3.2 Upstate 200 neg neg
k chains rabbit polyclonal Dako 50 pos pos
l chains rabbit Dako 30000 neg neg
MNDA mouse 235 provided by CNIO** 2 pos pos
MUM1 Protein mouse MUM1p Dako 50 pos pos
PAX 5 mouse 1EW Novocastra 50 pos/neg pos/neg
P53 Protein mouse DO-7 Novocastra 20 pos/neg pos/neg
Sox11 rabbit polyclonal Atlas Sigma 50 pos/neg pos/neg
TCL1A mouse 1–21 Santa Cruz 100 pos/neg pos/neg
TdT rabbit polyclonal Dako 30 neg neg
TRAcP mouse 26E5 Neomarkers 30 neg neg
doi:10.1371/journal.pone.0052811.t002
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Preparation of Formalin-fixed Paraffin-embedded (FFPE)
Cell Block and Immunohistochemical Staining
Briefly, 126106 cells were centrifuged, washed once in PBS and
then incubated for 15 minutes in 4% buffered formalin. Cells were
centrifuged again and resuspended in 1 ml of 1% low melting
point agarose at 37uC; then, they were poured into disposable
plastic moulds and cooled for ten minutes at +4uC. Solid agarose
blocks were put inside a histological cassette, with 4% buffered
formalin at room temperature, and then processed routinely as
tissue block; 4 mm-thick sections were cut from the block and
stained with ematoxilin-eosin to verify the quality of the cell
inclusion. Many sections from the block were immunolabeled with
the broad panel of antibodies described in Table 2. A 25% cut-off
was used to distinguish positive from negative. All samples were
processed by using a sensitive ‘Bond polymer Refine’ detection
system in automated Bond immunostainer (BondMax, Vision-
Biosystem, Menarini, Florence, Italy).
Establishment of the Mouse in vivo Model
Three month-old immunodeficient Rag22/2 c-chain2/2 mice
(Taconic animal models, New York’s River Valley, NY USA) were
injected either subcutaneously (s.c.) (n = 6) with 56106 VR09 cells,
resuspended in 0.2 ml PBS, or intravenously (i.v) (n = 6) with
0.56106 VR09 cells resuspended in 0.1 ml PBS. Animals were
checked three times a week for the development of tumors. When
s.c. tumors developed up to approximately 2 cm of diameter,
corresponding to a spheric volume of approximately 4.187 cm3,
mice were killed. Half of the tumor mass was frozen and half
included in paraffin according to standard procedures. Sections of
5–8 mm from each tumoral mass were prepared and analyzed for
morphology, immunohistochemistry and FISH. Paraffin sections
for immunohistochemistry were stained with a panel of antibodies,
as described above (Table 2). Moreover, a little portion of the
mass from two of six s.c injected mice, was dissected and
mechanically dissociated into single-cell suspension; 1.56106 cells
from each tumor were cultured in RPMI +10% FBS and
incubated as described above. Immunophenotipic analysis was
performed on secondary cell culture after two months of culture,
as previously described.
Figure 2. Immunophenotype. Immunophenotyping of VR09 cell line (grey and filled curves) and cell suspensions from in vivo tumor mass (black
and filled curves), as compared with isotype control (white curves).
doi:10.1371/journal.pone.0052811.g002
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Three of six mice injected i.v. were euthanized at +30 days,
while the others were sacrificed after four months from the
treatment. Spleen, liver, femurs, lymph nodes, lungs and bowel of
the i.v. injected animals were collected and included in paraffine.
Tissue sections were immunostained with antibodies against CD20
and CD138 to verify the presence on tumor infiltration. In
addition, immunophenotyping with anti-human CD19 and CD45
monoclonal antibodies and isotype controls was performed by
standard procedures on peripheral blood mononuclear cells of all
mice injected both s.c. and i.v.
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
in vivo studies were approved by Verona University Ethical
Committee for experimentation on animals (Prot. nu51 del 16/
06/11, D.lgs 116/92).
EBV Status Evaluation
The presence of EBV was assessed on both cells cultured in vitro
and cells obtained from the tumoral mass developing after in vivo
injection of VR09 cell line. Epstein-Barr virus-encoded RNA
(EBER) hybridization was performed on cytoinclusion by means of
specific fluorescein-conjugated EBER probes (Bond ISH EBER
Probe, Vision-Biosystem, Menarini, Florence, Italy). EBER
sequence was detected by anti-fluorescin antibody associated with
a sensitive ‘Bond polymer Refine’ chromogenic detection system in
an automated immunostainer (Bondmax, Vision-Biosystem, Me-
narini, Florence, Italy).
Figure 3. Cell line growth in vivo. (A) Spherical subcutaneous mass (arrow) in Rag-22/2 c-chain2/2 mice 36 days after VR09 cell line injection
(representative case). (B) Timing of tumor development in vivo (6 mice s.c. injected with 56106 cells/mouse).
doi:10.1371/journal.pone.0052811.g003
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To verify that EBV infection of VR09 derived directly from the
patient, the presence of EBV gene RPMS1 was detected by PCR
amplification on both DNA from the patient and VR09 cell line.
The reaction was performed in a final volume of 50 ml, containing
5 ml Taq Buffer Advanced (5 Prime, Hamburg, Germany),
5 pmol of each primer (listed in Table 1), 200 mM each dNTP
and 1.25 U of Taq DNA Polymerase (5 Prime). Cycling conditions
were 2 minutes at 94uC, 20 seconds at 60uC, 40 seconds at 68uC,
then a final elongation of 5 minutes at 68uC. PCR products were
analyzed on a 2100 Bioanalyzer (Agilent Technologies, Wald-
bronn, Germany), using the Agilent DNA1000 chip and reagents.
Electronic data were analyzed using the manufacturer’s software
(Agilent 2100 Expert).
Karyotyping and Fluorescence in situ Hybridization (FISH)
Cytogenetic analysis was performed with standard methods on
both cells cultured in vitro and cell suspensions from tumors
developing after in vivo injection of VR09 cell line: 10–
206106 cells were centrifuged, resuspended in RPMI 1640
medium containing 20% fetal bovine serum (FBS, Lonza,
Verviers, Belgium) and cultured for 24 hours. Before harvest,
0.15 mg/ml colchicin (Eur-Clone, Italy) was added. Chromosome
preparation and staining using QFQ technique was performed
according to standard protocols. Karyotypes were scored accord-
ing to the International System for Human Cytogenetic Nomen-
clature (ISCN) [14]. Images were captured with a ZEISS Axioplan
microscope (ZEISS, Jena, Germany) and evaluated by Cytovision
applied imaging system (Molecular Devices, New Milton).
Interphase cytogenetic FISH was performed on nuclei from
VR09 cell suspension and formalin-fixed and paraffin-embedded
tissue sections from in vivo tumor masses developing after in vivo
injection of VR09 cell line. The following kits were used: LSI
BCL-2 dual color probes for 14q32;18q21 (Abbott-Vysis, Olym-
pus), LSI CCND1 (11q13) break-apart probes (Abbott-Vysis,
Olympus), LSI IGH/CCND1 probe for 11q13-14q32.3 (Abbott-
Vysis, Olympus), LSI MYC dual color break-apart probe for 8q24
(Abbott-Vysis, Olympus), LSI C-MYC dual color probes for 8q24-
14q32 (Abbott-Vysis, Olympus) and CEP (centromeric) mapping
12p11.1-q11.1 (Abbott-Vysis, Olympus). Chromosome 9 probes
from human painting box kit (Spectral Imaging) were also used to
Figure 4. Representative histological markers detected on tumors. High magnification (20X) of histological sections of tumors developing
after in vivo injection of VR09 cell line. Lymphoid infiltrates display large size, plasmablastic-plasmacytic features and high Ki-67 index. Cells express
CD19, CD20, CD138, CD79a, IgM, IgG and EBV protein (EBER).
doi:10.1371/journal.pone.0052811.g004
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identify whole chromosome 9 on metaphases of cell derived from
in vivo tumor masses. The procedure was performed according to
the methods described elsewhere [15].
FISH slides were examined by using either Axioplan (Zeiss,
Germany) or Olympus BX61 (Olympus, Hamburg, Germany)
epifluorescent automated microscopes. The signals were recorded
using a CCD camera (Axiocam HRm, Zeiss and Digital Camera
Olympus), and score was assigned according to manufacturer’s
instructions, available in each commercial FISH kit.
Results
Establishment and Characterization of VR09 Cell Line
Primary cells proliferated very slowly during the first six weeks
of culture, with a consequent decline in cell number. Remaining
cells formed a few clusters of proliferation and started growing in
suspension forming small round clumps (Figure 1C). At ten weeks
of culture a stable proliferating cell line (designed VR09) was
established, with a doubling time of approximately 84 hours. May-
Gru¨nwald-Giemsa staining showed a wide cellular size spectrum,
from medium to large cells, with plasmacytoid features and
occasional bizarre shapes: cells had a round-ovoid, often eccentric
or moderately irregular nucleus, with compact chromatin and
abundant basophilic cytoplasm (Figure 1D). At present, VR09
cells grow in suspension in RPMI 1640 medium supplemented
with 10% heat-inactivated FBS without requiring any other
supplements, and can be vitally stored in a medium consisting of
60% RPMI 1640 medium, 30% heat-inactivated FBS and 10%
DMSO. Once thawed and put in culture, VR09 cell line grows
rapidly and maintains the same doubling time of the early culture.
Cells are optimally maintained at 500,000 and 1,000,000/mL cell
density and may be split 1:5 every 72 hours.
Immunophenotype and Immunohistochemistry
Immunophenotyping by flow cytometry was performed on
VR09 cell line at 10 weeks and one year after continuous culture,
resembling the phenotype of atypical B-cell chronic lymphopro-
liferative disease with plasmacytic features found in the patient. In
particular, cells were CD45+, CD19+, CD20+, CD22+, CD23+,
CD43+, CD38+, CD138+, IgD+, IgM+, IgG+ and kappa chains+,
and negative for CD3, CD5, CD10, CD25, CD79b, CD103,
FMC7 and lambda chains (Figure 2); Zap-70, as expected, was
not expressed. VR09 surface markers remained unchanged over
time, with the exception of CD20, whose expression had a 1 log
increase as compared to starting culture.
Results of immunohistochemistry performed on FFPE cell block
are summarized in Table 2: all the markers shown by flow
cytometry were confirmed, with the exception of IgG and CD38
expression that resulted negative by immunohistochemistry;
proliferation index (Ki-67+ cells) was about 40%. In addition,
cells were positive for Bcl-2, MNDA [16] and MUM1, and
negative for Bcl-6, Cyclin D1, Annexin A1, DBA44, GCET1,
ZAP-70, TdT and TRAP; other markers, such as PAX-5, Sox11,
FOXP1 and TCL1, were weakly and variably expressed. In
summary, neoplastic cells displayed a late B-cell phenotype
(MNDA+, FOXP1+, IRF4/MUM1+, cyK+, CD138+), while
germinal center markers (Bcl-6, CD10, TCL1, GCET1) and
immature B-cell markers (TdT) were negative. Cyclin D1 was
included to exclude the remote possibility of a blastoid variant of
mantle cell lymphoma, and also because plasma cell myeloma can
be cyclin D1-positive. Hairy cell leukemia markers (Annexin A1,
DBA44, TRAP) were investigated to exclude the very remote
possibility of evolution from hairy cell leukemia (in consideration
of the clinical setting).
Cell Cycle
DNA content of VR09 cell line was analyzed at six months and
one year of culture. High S-phase rate was observed (diploid S
22.66%), in absence of tetraploid or aneuploid peak, as compared
to the control (diploid S: 1.64%).
IVGH, TP53, CARD11, CD79B and MYD88 Mutation
Analysis
VR09 cell line and the DNA from the patient showed the same
VH3-7/D4-23/JH4 gene rearrangement. The comparison of the
sequence with published germline sequences showed 95.7%
identity in both VR09 cell line and DNA from the patient, with
evidence of somatic hypermutation (SHM) in the VH region,
defined as more than 2% mutations as compared to germline
sequences. The analysis of the sequences obtained from both
strands of cDNA and compared with the published TP53 sequence
(U94788.1) showed that this sequence in VR09 cell line was wild-
type (data not shown). CARD11 sequence was compared to the
published one (NM_032415): VR09 cell line showed a silent
heterozygous mutation leading to D533D variation in the protein
linker region. Finally, VR09 cell line expressed all the three
isoforms of the CD79B gene (NM_000626.2; NM_021602.2;
NM_001039933.1): cDNA sequence analysis showed that variants
1 and 3 had an homozygous silent mutation in exon 3 leading to
C122C variation in the Ig-like V-type protein domain, involving
the disulfide bond; moreover, variant 2 had an Alanine insertion in
the exon 2b corresponding to the protein signal peptide region.
The analysis of exons 1 to 5 of MYD88 showed no mutations
compared to the reference sequence (NG_016964).
Figure 5. EBV positivity in the original tumor and in the VR09
cell line. PCR products analysis by Agilent 2100 Bioanalyzer showed
the presence of the same 151 bp specific amplicon for EBV RPMS1
gene, thus demonstrating that EBV infection was present in the original
cells from patient. A normal DNA from pancreas was used as negative
control.
doi:10.1371/journal.pone.0052811.g005
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Mouse Model
All six mice injected s.c. with VR09 cell line developed spherical
tumor masses around the site of injection by 34–74 days after
treatment and were sacrificed 10 days later. Subcutaneous mass
and tumor incidence in vivo are shown in Figure 3. Cells from
subcutaneous masses were evaluated by H&E and Giemsa
staining: cells ranged from medium to large size, with irregular
Figure 6. Karyotyping and FISH of secondary culture. (A) Trisomy of chromosome 12 and structural chromosome aberration involving
chromosomes 7 and 9 on secondary culture detected by karyotype; (B) Chromosome 9 staining by FISH of secondary culture.
doi:10.1371/journal.pone.0052811.g006
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nuclei, condensed chromatin without nucleoli and basophilic
cytoplasm. Immunohistochemistry showed no significant differ-
ences in tumor cell immunophenotype as compared to VR09 cell
line in culture (Table 2 and Figure 4).
Cells suspensions obtained by disaggregation of in vivo tumor
masses showed proliferative capacity when cultured with the same
procedure used for primary VR09 cell line. Again, cells appeared
as small and round clumps with plasmacytoid features and bizarre
shape: immunophenotyping on these cells after two months of
continuous secondary culture did not show any significant change
of cell surface marker expression as compared to primary VR09
cell line (Figure 2).
Of the six i.v. injected mice, three were euthanized after 30 days
from injection and the other 3 after four months: histopathologic
examination of spleen, liver, femurs, lymph nodes and lungs did
not show any evidence of tumor infiltration. In addition, no
circulating human CD45/CD19-positive cells were detected in
peripheral blood of both s.c. and i.v. injected mice.
EBV Status
EBV RNA evaluation was performed on FFPE cell blocks and
tumoral masses by using a fluorescein-conjugated probe coupled to
chromogenic detection (Bond ISH EBER Probe, Vision-Biosys-
tem, Menarini, Florence, Italy). In situ hybridization for EBV-
encoded RNA (EBER) showed a clear nuclear signal in both
VR09 cell line and tumors (Table 2 and Figure 4).
Analysis of the RPMS1 gene PCR products, performed on both
DNA from patient and VR09 cell line, showed the same 151 bp
specific amplicon (Figure 5), thus showing that EBV infection was
already present at the beginning of culture.
Karyotyping
Chromosome analysis performed at 10 weeks and one year of
continuous culture showed a male karyotype with 47 chromo-
somes. All metaphases exhibited trisomy of chromosome 12.
Karyotype was repeated on secondary cell cultures obtained by
disaggregation of in vivo tumor masses, thus revealing the presence
of additional structural chromosome aberration involving chro-
mosomes 7 and 9, i.e. 47, XY, der(7)(9qter-.9p23::7p13-.7qter),
+der(7)(9qter-.9p23::7p13-.7qter), 29, +12 (Figure 6A).
Fluorescence in situ Hybridization (FISH)
Adjacent or fused fluorescent signals (LSI BCL-2) were found in
5% of nuclei on tissue sections; this percentage is below the
established 10% signal threshold for considering a case positive
(adjacent signals are generated by random overlapping of genomic
regions). No break-apart fluorescent signals were found for LSI
CCND1 (11q13) and LSI MYC (8q) probes on tissue sections. No
adjacent or fused fluorescent signals were found for LSI IGH/
CCND and LSI C-MYC dual color probes (4% of nuclei, below
threshold). Trisomy of chromosome 12 was found in 45% of
nuclei. The rearrangement involving chromosomes 9 and 7
detected by karyotyping on cell suspension from in vivo tumor mass
was confirmed by fluorescent signals derived from hybridization of
chromosome 9 DNA probes to target chromosome 9 (chromo-
some 9 paint) (Figure 6B). The main features of VR09 cell line
are summarized in Table 3.
Table 3. Summary of VR09 cell line features.
Parameter Features
Cell Line
Name of cell line VR09
Cell line type Lymphoid
Cell phenotype CD19+ CD20+ CD79a+ CD79b+/2 CD138+ cyclin D1- Ki67 80% IgM+ IgD+ MUM1+ MNDA+ CD102 CD22+ CD23+ CD43+
K+, l2 Bcl2+ Bcl62
Cytogenetic karyotype Trisomy of chromosome 12
Mutation analysis VH3-7/D4-23/JH4
Tumorigenic capacity Subcutaneously growth into immunodeficient Rag22/2 c-chain2/2 mice
Clinical data
Primary disease of patient Atypical B-cell chronic lymphoproliferative disease with plasmacytic features
Disease Status At diagnosis
Patient data (age, race, sex) 75-year old Caucasian man
Source of material Bone marrow
Year of establishment 2008
Cell culture data
Culture Medium RPMI 10% FBS
Subcultivation routine Maintained at 0.5–161.06 cells/mL; 1:5 split every 72 hours
Minimum cell density 0.56106 cells/mL
Maximum cell density 1.06106 cells/mL
Doubling time 84 hours
Cell storage condition 60% RPMI 1640 medium, 30% heat-inactivated FBS and 10% DMSO
In situ morphology medium-to-large sized cells, plasmacytoid features and occasional bizarre shapes; round clumps in suspension
Viral status EBV-positive
doi:10.1371/journal.pone.0052811.t003
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Discussion
We describe here the establishment and molecular character-
ization of novel human EBV-positive DLBCL cell line with
plasmacytic differentiation obtained from a patient with atypical
B-cell chronic lymphoproliferative disease with plasmacytic
features.
Human B-lymphoid cell lines are extensively used world wide as
models in studies of various aspects of B cell biology and as a tools
in research on the pathogenesis of leukemia and lymphoma.
Nevertheless, the efficiency establishment of new leukemia and
lymphoma cell line is rather low and remains a random process
[1]. Sometimes, the spontaneous proliferation and immortalization
of normal or malignant cells in vitro is due to EBV infection. It is
well known for several decades that infection of normal B cell with
EBV leads to establishment of lymphoblastoid cell line, thus
confirming its oncogenic potential [17]. EBV is associated to
several malignancies in vivo and may lead to spontaneous growth
and transformation of malignant cells in vitro [2]; nevertheless,
lymphoproliferative cell lines from CLL-like chronic lymphopro-
liferative disorders have never been reported, unless infected by
EBV or in prolymphocytoid transformation [18]. The establish-
ment of VR09 cell line was likely due to EBV infection; in fact, as
EBV was already present in patient’s B cells, we can reasonably
assume that the infection drove the transformation into DLBCL
once cultured in vitro and injected into mice, thus excluding
a culture-dependent contamination by EBV. Indeed, the Associ-
ation between EBV infection and indolent B-cell neoplasms, such
as chronic lymphocytic leukemia, marginal zone lymphoma,
lymphoplasmacytic lymphoma has been reported [4,19,20] Thus,
the positivity of EBV in VR09 cell line is not surprising. Moreover,
some studies showed that cases of DLBCL developed from low-
grade lymphoproliferative diseases are EBV-positive and that EBV
may have a potential role, although not yet completed defined, in
the progression of the indolent disease [21,22].
Unfortunately, we lack much information about the patient;
however, bone marrow cell morphology and immunophenotype
are in agreement with the diagnosis of atypical, non-CLL B-cell
chronic lymphoproliferative disease with plasmacytic features.
Low-grade B-cell lymphoproliferative disorders, such as CLL/
small lymphocytic lymphoma and marginal zone B-cell lymphoma
may have overlapping features, thus making the differential
diagnosis sometimes difficult. Furthermore, many types of small B
lymphoid neoplasms can display plasmacytic differentiation and
a phenotype resembling lymphoplasmacytic lymphoma; the latter
consists of small lymphocytes, plasmacytoid lymphocytes and
plasma cells expressing IgM and pan-B-cell antigens, such as
CD19, CD20 and CD22, and usually negative for CD5, CD10
and CD23. As we lack information about serum IgM paraprotein,
we concluded as a case of atypical B-chronic lymphoproliferative
disease with plasmacytic differentiation, rather than a plasmacytic
lymphoma.
Among lymphoproliferative disorders, VR09 cell line presents
features of DLBCL with plasmacytic differentiation, with medium
to large sized and plasmablastic/plasmacytic-like cells, high Ki-67
index and activated phenotype according to Hans’ and new
immunostaining algorithm [9]. Moreover, cells are positive for
MUM1, CD38, and CD138, thus suggesting a terminal-B cell
differentiation.
Although lymphoplasmacytic lymphoma and other lymphopro-
liferative disease with plasmacytic differentiation may develop into
diffuse large B cell lymphoma, similarly to CLL, the frequency of
transformation is low [22]. Consequently, VR09 cell line can be
useful as a model of DLBCL variant corresponding to a very late
or activated stage of B cell maturation [23], i.e. the early post-
germinal stage differentiation, not entirely terminally differentiat-
ed.
Despite the aggressive transformation of indolent disease is not
always clonally related to original disease, some data are indirectly
consistent with the hypothesis of clonal evolution: in fact, VR09
cell line maintains the immunophenotype and plasmacytoid
features of the primary cells at diagnosis, displays the presence
of the same clonal gene rearrangement found in patient’s DNA
and has a tumorigenic capacity in vivo; the latter feature strongly
suggests its malignant behaviour. VR09 cell line grow sub-
cutaneously without dissemination in peripheral blood and no
engraftment when it is administrated i.v. This strange peculiarity
could be simply due to the in vivo model used, i.e. Rag22/2 c-
chain2/2 mice. They are immunodeficient mice with C57B16/10
background devoid of functional B and T cells because of the
complete lack of function of the V(D)J recombinase enzyme
system, and displaying deficient innate immunity due to the
absence of c chain of interleukin-2-receptor [24]. This model has
the advantage to show a stable phenotype without developing
spontaneous tumors, as compared to SCID mice [25]. Indeed,
VR09 cell line injection led to 100% incidence of developing
tumors in vivo, always maintaining the same features.
We found trisomy of chromosome 12 in our model. This
aberration is often detected in chronic lymphocytic leukemia
[26,27] and in other chronic B cell malignancies, including
sometimes lymphoplasmacytic lymphoma. We also found an
additional chromosomal abnormality involving chromosomes 7
and 9 after secondary culture: genetic alterations of cell lines are
usually stable over the time, but it is debated whether cell line may
acquire additional rearrangements in culture [1].
We also found a synonymous variant of CD79B involving the
insertion of Alanine in the exon 2b of variant 2. This variant may
be physiological since it has been detected in other isoforms;
however, it has never been described before. Moreover, a recent
study suggested that also synonymous variants may be involved in
the pathogenesis of some diseases [28]; therefore, one could
speculate that this novel variant of CD79B gene could be involved
in the pathogenesis of lymphomas. VR09 cell line did not display
the common missense mutations of Card11, usually involved in
the constitutive activation of NF-kB pathway in some cases of
human activated-B-cell like DLBCL [29]. However, the detection
of synonymous mutations of Card11 reveals the accuracy of
sequencing method. Interestingly, VR09 cell line showed un-
mutated Myd88 gene, differently from what described in recents
reports [11,12], thus suggesting that lymphomas with plasmacytic
features may have different gene patterns.
In conclusion, VR09 is a new cell line of activated DLBCL with
plasmacytic differentiation that grow as solitary tumor once
injected s.c. in immunodeficient mice. This model could be useful
for further studies about the development of DLBCL in patients
with low-grade B-cell lymphoproliferative disorders with plasma-
cytic differentiation, which is a rare but possible event in clinical
practice.
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